A look at the shareholders of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are private equity firms with 46 ...

Reneo Pharmaceuticals Inc (NASDAQ:RPHM) anticipates pivotal STRIDE study topline data in December 2023. Q3 2023 saw a net loss of $19.2 million, a deeper loss compared to Q3 2022's $13.0 million.

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new ...

Reneo Pharmaceuticals RPHM, a clinical-stage company, announced the failure of the mid-stage pivotal STRIDE study of its investigational candidate, mavodelpar (REN001), to treat primary mitochondrial ...

Reneo Pharmaceuticals (NASDAQ:RPHM) to merge with privately-held OnKure Inc, in an all-stock deal aimed at creating a Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) and OnKure, Inc. is fair to Reneo ...

Robert W. Baird analyst Brian Skorney maintained a Buy rating on Reneo Pharmaceuticals (RPHM – Research Report) yesterday and set a price target of $28.00. The company’s shares opened today at $6.41.

MONSEY, N.Y., May 13, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the proposed merger of Reneo Pharmaceuticals, Inc. (RPHM) (“Reneo”) with privately held OnKure, Inc.